ERBB2 and breast cancer: Because the large majority of BC patients are diagnosed with early, hormone receptor positive/HER2-negative cancers21, we focus on this BC subset and provide a detailed interrogation of EC heterogeneity in matched tumoral and peri-tumoral tissues.